公开(公告)号：US20220000864A1

公开(公告)日：2022-01-06

申请号：US17294915

申请日：2019-11-19

申请人： 11949098 CANADA INC.

发明人： Jean TCHERVENKOV ,  Ahmed FOUDA ,  Steven PARASKEVAS ,  Sarita NEGI

IPC分类号： A61K31/498 ,  C07D409/06 ,  C07D409/14 ,  C07D409/12 ,  C07D409/04 ,  A61K31/506 ,  A61K31/4155 ,  A61K31/496 ,  A61K31/381 ,  C07D333/66 ,  A61K31/465 ,  A61K31/4178 ,  A61K31/497 ,  A61K31/519 ,  A61K31/52 ,  A61K31/7068 ,  A61K31/513 ,  A61K31/655 ,  A61K31/131 ,  A61K31/196 ,  A61K31/198 ,  A61K31/17 ,  A61K31/675 ,  A61K31/255 ,  A61K31/047 ,  A61K31/7008 ,  A61K31/407 ,  A61K33/243 ,  A61K31/704 ,  A61K38/14 ,  A61K38/12 ,  A61K31/5517 ,  A61K31/475 ,  A61K39/395 ,  A61K35/17 ,  A61K38/19 ,  A61K31/44 ,  A61K31/404 ,  A61K31/436 ,  A61K45/06 ,  A61P37/06

摘要： The invention encompasses the novel class of compounds represented by the Formula (I), (II), (III) and (IV) below, which are modulators of RORγt: The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing autoimmune diseases and antibody mediated rejection in a patient in need thereof.